<DOC>
	<DOCNO>NCT03082599</DOCNO>
	<brief_summary>In July 2016 , FDA approve extended depth focus ( EDOF ) IOL ( Tecnis Symfony , Abbott Medical Optics ) help improve sharpness vision near , intermediate far distance reduce need glass cataract surgery . It available non-toric version toric version patient astigmatism . The difference lens multifocal ( MIOL ) counterpart EDOF , similarly monofocal IOL , one focal point ( elongate EDOF ) multifocals 2 focal point ; therefore , less halo glare problem . Pivotal trial result Symfony compare monofocal IOL show similar uncorrected distance visual acuity ( UCDVA ) , good intermediate ( 77 % vs. 34 % 20/25 uncorrected intermediate visual acuity - UCIVA ) near vision ( Symfony patient able read two additional , progressively small line compare monofocal IOL ) .A One potential disadvantage EDOF IOL compare MIOL visual performance near.B One option deal potential shortcoming set non-dominant eye small residual myopic error ( -0.50 D ) C refer nano-vision mini mono-vision .</brief_summary>
	<brief_title>Symfony Toric Intraocular Lens Visual Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Astigmatism</mesh_term>
	<criteria>1 . Subject undergoing bilateral cataract extraction intraocular lens implantation . 2 . Willing able provide write informed consent participation study 3 . Willing able comply schedule visit study procedure . 4 . Scheduled undergo standard cataract surgery topical anesthesia eye within 615 day surgery . 5 . Subjects require IOL power range +5.0 D +34.0 D . 6 . Potential postoperative visual acuity 0.2 logMAR ( 20/32 Snellen ) good eye . 1 . Severe preoperative ocular pathology : amblyopia , rubella cataract , proliferative diabetic retinopathy , shallow anterior chamber , macular edema , retinal detachment , aniridia iris atrophy , uveitis , history iritis , iris neovascularization , medically uncontrolled glaucoma , microphthalmos macrophthalmos , optic nerve atrophy , macular degeneration ( anticipated best postoperative visual acuity le 20/30 ) , advance glaucomatous damage , etc . 2 . Uncontrolled diabetes . 3 . Use systemic topical drug know interfere visual performance . 4 . Contact lens use active treatment portion trial . 5 . Any concurrent infectious/noninfectious conjunctivitis , keratitis uveitis . 6 . Clinically significant corneal dystrophy 7 . History chronic intraocular inflammation . 8 . History retinal detachment . 9 . Pseudoexfoliation syndrome condition potential weaken zonule . 10 . Previous intraocular surgery . 11 . Previous refractive surgery . 12 . Previous keratoplasty 13 . Severe dry eye 14 . Pupil abnormalities 15 . Subject may reasonably expect require secondary surgical intervention time study ( yttrium aluminum garnet ( YAG ) capsulotomy , i.e . LASIK ) 16 . Anesthesia topical anesthesia ( i.e . retrobulbar , general , etc ) . 17 . Any clinically significant , serious severe medical psychiatric condition may increase risk associate study participation may interfere interpretation study result . 18 . Participation ( current participation ) ophthalmic investigational drug ophthalmic device trial within previous 30 day prior start date trial .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>